# EDGAR Filing Document

**Accession Number:** 0001645469
**File Stem:** 0001437749-25-028477
**Filing Date:** 2025-9
**Character Count:** 2334
**Document Hash:** 55e9d1a011b3b41c6349445e3a7d1e20
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-028477.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001437749-25-028477

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Monopar Therapeutics
- **CENTRAL INDEX KEY:** 0001645469
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 320463781
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 SKOKIE BLVD SUITE 350
- **CITY:** WILMETTE
- **STATE:** IL
- **ZIP:** 60091
- **BUSINESS PHONE:** 8473880349

**MAIL ADDRESS:**
- **STREET 1:** 1000 SKOKIE BLVD SUITE 350
- **CITY:** WILMETTE
- **STATE:** IL
- **ZIP:** 60091

**Monopar Therapeutics Inc.**<br> 1000 Skokie Blvd., Suite 350

Wilmette, Illinois 60091

September 5, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission<br> Division of Corporation Finance

100 F Street, N.E.<br> Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | Monopar Therapeutics Inc.<br> Registration Statement on Form S-3<br> File No. 333-289947 |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Act</u>"), Monopar Therapeutics Inc. (the "<u>Company</u>") hereby requests that the effective date of the above-referenced registration statement (the "<u>Registration Statement</u>") be accelerated to September 9, 2025, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

We request that we be notified of such effectiveness by a telephone call to John J. Harrington of Baker & Hostetler LLP, counsel to the Company, at (216) 861-6697 and that such effectiveness also be confirmed in writing.

---

| | |
|:---|:---|
| Very truly yours,<br>Monopar Therapeutics Inc. | Very truly yours,<br>Monopar Therapeutics Inc. |
| By:  | /s/ Chandler D. Robinson |
|  | Chandler D. Robinson |
|  | Chief Executive Officer |

---